Guillain Barre syndrome is a rare but serious neurological disease that requires hospitalization in almost all victims and has no known cure. With such a description, employers and people, in general, might be a little cautious about proceeding with the Johnson & Johnson Covid vaccine. The U.S. Food and Drug Administration announced on July 12 that Guillain Barre syndrome is a rare side effect of this vaccine.
It sounds scary, and it might make you think about not encouraging your employees to receive their vaccine, but take a step back. Don’t panic. Here’s what employers need to know.
To keep reading, click here: Guillain Barre May Be a Tragic, Though Rare, Side Effect. Employers Should Promote Covid Vaccines Anyway
3 thoughts on “Guillain Barre May Be a Tragic, Though Rare, Side Effect. Employers Should Promote Covid Vaccines Anyway”
There is no cure for Guillain-Barre Syndrome (GBS). However, it is highly-treatable, and most people fully recover. A small number suffer permanent nerve damage. GBS is — exceedingly — rare, but males over the age of 50 are most susceptible. Were I a male over 50, or a female of child-bearing age — susceptible to the also exceedingly-rare blood clot complication of the Johnson & Johnson vaccination — I would choose the Pfizer or Moderna vaccines instead. But, obviously, all three of the US vaccines are much safer than COVID-19
“and most people fully recover.” Yup, and I feel like this is the part that alarmists (intentionally in some cases) overlook.
And then there is this…
Comments are closed.